leadf
logo-loader
viewAIM ImmunoTech Inc

AIM ImmunoTech reveals most recent advancements with its potential coronavirus treatment

AIM ImmunoTech Inc (NYSE American: AIM) CEO Thomas Equels tells Proactive the Florida-based biopharma group is working on setting up its pre-clinical structure to allow it to begin clinical trials to treat the coronavirus with its lead drug Ampligen.

What's more, Equels says the firm recently inked a deal to research vaping devices as a vehicle for Ampligen to treat the coronavirus.

Quick facts: AIM ImmunoTech Inc

Price: 2.02 USD

NYSE:AIM
Market: NYSE
Market Cap: $82.19 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc named herein, including the promotion by the Company of AIM ImmunoTech Inc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

AIM ImmunoTech says medical journal published data showing Ampligen...

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) CEO Tom Equels tells Proactive that data has been published detailing how its drug Ampligen could have a considerable impact on people living with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) when administered in the disease’s early...

on 11/09/2020

2 min read